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Multiple sclerosis (MS) is a gait disorder characterized by acute episodes of neurological defects leading to progressive
disability. Patients with MS have multiple risk factors for osteoporotic fractures, such as progressive immobilization, long-term
glucocorticoids (GCs) treatment or vitamin D deﬁciency. The duration of motor disability appears to be a major contributor
to the reduction of bone strength. The long term immobilization causes a marked imbalance between bone formation and
resorption with depressed bone formation and a marked disruption of mechanosensory network of tightly connected osteocytes
due to increase of osteocyte apoptosis. Patients with higher level of disability have also higher risk of falls that combined with
a bone loss increases the frequency of bone fractures. There are currently no recommendations how to best prevent and treat
osteoporosis in patients with MS. However, devastating eﬀect of immobilization on the skeleton in patients with MS underscores
the importance of adequate mechanical stimuli for maintaining the bone structure and its mechanical competence. The physical
as well as pharmacological interventions which can counteract the bone remodeling imbalance, particularly osteocyte apoptosis,
will be promising for prevention and treatment of osteoporosis in patients with MS.
1.Introduction
Osteoporosis is a condition of impaired bone strength which
leads to increased risk of fracture [1]. The enhanced bone
fragility reﬂects the integration of the amount of bone (bone
mass) and bone quality. Bone quality depends on its macro-
and microarchitecture and on the intrinsic properties of
the materials that comprise it (e.g., matrix mineralization,
microdamage accumulation, or collagen quality) [2]. Bone
is continually adapting to changes in its mechanical and
hormonal environment via the process of bone remod-
eling. Bone remodeling maintains bone structure and its
mechanical competence by removing damaged bone and
replacing it with new bone and thus restores bone’s material
composition, micro-, and macroarchitecture. This process
depends on the normal production, work and lifespan of
osteoclasts, osteoblasts, and osteocytes. Thus, diseases and
drugsthathaveanimpactonbonecellsandboneremodeling
will inﬂuence bone’s structure and its resistance to fracture
[3]. Multiple sclerosis (MS) is a chronic progressive disease
aﬀecting the myelin sheath covering of nerve ﬁbers in the
brain and spinal cord, leading to functional impairments
such as visual impairment, abnormal walking mechanics,
poor balance, muscle weakness, fatigue, and progressive
immobilization [4]. The resultant functional impairments
lead to frequently falls [5]. The disease aﬀects mainly young
adults (20 to 40 years) and its incidence is more frequent in
women (approximately 2:1) [6] .I t sp r e v a l e n c er a n g e sf r o m
2 to 150 patients at 100000 [7]. Impaired mobility or lack
of weight-bearing physical activity reduced mechanical stress
onbone,whichcausesamarkedimbalanceinboneremodel-
ingwithadisruptionofosteocytesnetwork[8].Management
of MS requires long-term disease-modifying therapy, such
as glucocorticoids (GCs) with a further negative eﬀect on
bone remodeling and bone strength. Secondary osteoporosis
may develop and low-trauma fractures occurring in patients
with MS more frequently than in healthy controls [9–15].
Fractures and their sequelae can have important personal as
well as (economic) implications for society. Therefore, the
attentionontheissueofbonehealthamongpatientswithMS
iswarranted.Thispaperexaminestheunderlyingpathogenic
mechanisms of osteoporosis in patients with MS as well as
its management. Understanding the causes associated with
decreased bone strength in patients with MS will help in the
optimal therapeutic intervention.2 Journal of Osteoporosis
2. Prevalence of Osteoporosis in Patients with
Multiple Sclerosis
The analysis of a registry of 9029 patients with MS in the
USA found that 27.2% responders reported low bone mass,
and more than 15% of responders reported a history of
fracture [9]. Most studies in patients with MS evaluated
BMD in comparison with the control group of healthy
subjects and showed signiﬁcantly lower BMD in patients
with MS than in controls [11–16]. Several of these studies
were shown that vertebral BMD is aﬀected to a lesser degree
than femoral BMD [11, 12, 16]. The low BMD in MS
patients involve both sexes [15]. Interestingly, one study in
men with MS reported low BMD (osteoporosis) in 37.5%
(15 out of 40) and 21% (8 out of 38 patients) had vertebral,
rib, or extremities fractures [15]. Patients with progressive
forms of MS showed a more severe loss of BMD than those
with relapsing-remitting MS [12]. Fracture incidence in
patients with MS evaluated only few studies. Cosman group
found fracture rates of 22% in patients with MS compared
with 2% in controls [11]. It remains unexplained whether all
patients with MS are more susceptible to osteoporosis and
fractures; for example, there is evidence that patients with
a low expanded disability status scale (EDSS) score did not
show any signiﬁcant diﬀerence in BMD with comparison
with healthy control subjects [17, 18]. Therefore, further
elucidation is needed to qualify which risk factors are most
responsible for a bone loss in patients with MS.
3. Pathogenic Mechanisms
Boneremodelingisunderwaythroughoutlifeandmaintains
bone strength by removing damaged bone and replacing it
with new bone and thus restores bone’s micro- and macroar-
chitecture. This process depends on the normal production,
work, and lifespan of osteoclasts, osteoblasts, and osteocytes
[19]. Chronic diseases, such as MS, may signiﬁcantly disturb
the process of bone modeling and remodeling with resulting
bone loss, deterioration of bone’s quality and increased
frequency of fractures [20, 21]. Secondary osteoporosis
and low-trauma fractures occur in patients with MS more
frequently than in healthy controls [9, 11]. The underlying
pathogenic mechanisms of the osteoporosis in patients with
MS are probably based on the progressive immobilization,
long-term GCs treatment, vitamin D deﬁciency, skeletal
muscle atrophy and possibly on the presence of various
cytokines involved in the pathogenesis of MS [10]. In
addition, chronic use of other drugs, such as antidepressants
may contribute to the development of osteoporosis and
fractures [22]. The functional impairments also leads to an
increased risk of falling that, combined with bone loss and
impaired quality of bone mass, can increase the frequency of
bone fracture in individuals with MS [11].
3.1. Disability. Mechanical loading is an important factor
controlling bone mass. Increased bone loss in immobilized
subjects is well-recognized complication in patients after
spinal cord injury with tetraplegia [23, 24], in bedridden
patients, or in astronauts [25], whereas localized bone
loss is well documented in patients with regional disuse,
for example, after fracture itself. Immobilization causes an
overall progressive bone loss at a similar rate to osteoporosis
caused by estrogen deﬁciency, but at the same amount of
induced bone loss, disuse led to more deteriorated bone
structureandmechanicalpropertiesthanestrogendeﬁciency
[26]. The available studies showed that cortical thinning and
substantial decline of trabecular bone density account for
increased bone fragility [27–29]. The duration and degree
of motor disability appears to be a major contributor to
the pathogenesis of secondary osteoporosis in patients with
MS. The degree of disability measured by the Kurtzke EDSS
score signiﬁcantly correlated with BMD in patients with MS
[11]. Speciﬁcally, site-speciﬁc eﬀects of motor disability were
documented in MS patients, and EDSS correlated mainly
with BMD in the hip but not in the lumbar spine [14].
In wheelchair-bound patients, an atrophy of hip muscles
aﬀects proximal femur, while BMD of lumbar spine is not
decreased because of its adequate mechanical stimulation
by the trunk and back muscles in the upright position.
Similarly, patients with spinal cord injury lose BMD mainly
at femoral sites [30]. Also, hemiplegic patients showed a
signiﬁcant loss of BMD in both trabecular and cortical bone
at the forearm and at the neck and great trochanter on the
paretic hip [31]. Higher total body bone mineral content
was documented in ambulatory patients (EDSS score ≤ 6.5)
compared with nonambulatory patients (EDSS score ≥ 7.0)
[12, 13]. Also, higher prevalence of osteoporosis was found
in nonambulatory patients [32]. In male patients, a positive
correlation has been observed between BMD and both EDSS
score (correlation with femoral and also vertebral BMD) and
BMI (correlation with femoral BMD only). There was shown
that also EDSS score and BMI two years prior to the study
could be used as future indicators of low BMD [15].
A reduced mechanical stress on bone causes a marked
imbalance in bone remodeling with a transient increase in
bone resorption (which occurs initially) and a decrease in
bone formation (which is sustained for a longer duration)
[25, 33, 34]( Table 1). The mechanism causing this decrease
in bone formation probably lies in the reduction of mechan-
ical stress during immobilization which results in a marked
disruption of osteocytes network due to increase of osteocyte
apoptosis. Osteocytes represent 95% of all bone cells and
form a mechanosensory system which is based on a three-
dimensional network of tightly interconnected osteocytes
entombed in mineralized bone matrix [35]. Disruption
of this system aﬀects probably several aspects of bone
homeostatic system, such as mechanosensitivity, mechan-
otransduction, and basic multicellular units responsible for
bone remodeling [36]. The immobilization-induced osteo-
cyteapoptosisisfollowedbyosteoclastogenesisandincreased
bone resorption [37]. While molecular mechanisms of
disuse osteoporosis are not well understood, recent evidence
found that mechanical unloading caused upregulation of
Sost gene in osteocytes and increased levels of sclerostin
(product of Sost gene) [38]. Sclerostin is responsible for the
inhibition of Wnt/beta-catenin signaling in vivo and for the
suppressed viability of osteoblasts and osteocytes. Interest-
ingly, sclerostin-deﬁcient mice (Sost −/−) were resistant toJournal of Osteoporosis 3
Table 1: Changes in bone cells metabolism and in bone mass/
structure in patients with long-term immobilization.
Increased Decreased
Osteocytes Apoptosis Metabolism and function
Repair of microdamage
Osteoblasts Apoptosis Activity
Synthesis of type I collagen
Osteoclasts Activity Apoptosis
Bone homeostasis Remodeling rate
Bone resorption Bone formation
Bone mineral density∗
Cortical thickness∗
Cortical density∗
Trabecular density∗
∗The anatomic location and function of the bone in the skeleton account
for the magnitude of skeletal response to immobilization.
mechanical unloading-induced bone loss [38]. Importantly,
the administration of sclerostin neutralizing antibody in
experimentalmodelofimmobilizationresultedinadramatic
increaseinboneformationandadecreaseinboneresorption
that led to increased trabecular and cortical bone mass [39].
Osteocytes are also necessary for targeted bone remodeling
to avoid microdamage accumulation, which could lead
to whole-bone failure. Recently, Waldorﬀ et al. showed
that osteocyte apoptosis may be insuﬃcient for repair of
microdamage without the stimulation provided through
physiologic loading [40]. MS aﬀects a wide range of neuro-
logicalfunctionandmostofpatientswithMShaveabnormal
muscle strength, impaired balance, and gait control which
leads to frequent falls [5, 41] that combined with a bone loss
increase the frequency of bone fractures. Imbalance is also
often the initial symptom of MS. The pathogenesis is not
completelyunderstoodyet.Itwasdemonstratedthatchanges
in postural control in most patients with MS are probably
the result of slowed aﬀerent proprioceptive conduction in
the spinal cord [5]. Disuse, inﬂammatory changes, as well as
GCs treatment or vitamin D deﬁciency, may also contribute
to weakness and loss of muscle strength and thus to frequent
falling.
3.2. Glucocorticoids (GCs). GCs are frequently used to
control MS relapses. Oral GCs treatment in patients with
MS may increase the risk of osteoporosis. Epidemiological
studies showed that fracture risk is increased rapidly after
starting oral GCs treatment and is related to the dose and
duration of GCs exposure [42]. Doses as low as 2.5–5mg
of prednisolone equivalents per day can be associated with
a 2.5-fold increase in vertebral fractures, and the risk is
greater with higher doses used for prolonged periods [43].
Bone loss due to GCs treatment is steep during the ﬁrst
12 months and more gradual but continuous in subsequent
years. However, the fracture risk returns towards baseline
levels after discontinuation of oral GCs treatment [44]. The
mechanism of osteoporosis in patients on GC treatment is
complex [45]( Table 2). However, the contribution of other
risk factors, such as vitamin D insuﬃciency and physical
disability confounds the assessment of GCs eﬀects on bone
in patients with MS.
Repeated pulses of high-dose methyprednisolone in MS
patientsdidnotresultinasubsequentdecreaseinBMD[18];
however, the risk of osteoporotic fractures remains slightly
increased in patients undergoing cyclic GCs treatment at
high doses [47]. High-dose, short-term intravenous GC
regimens cause an immediate and persistent decrease in
bone formation and a rapid and transient increase of bone
resorption [48]. In fact, GCs may increase proresorptive IL-
6 signaling as well as increase the expression of receptor
activator of NF-κB ligand (RANKL) and decrease the
expression of its soluble decoy receptor, osteoprotegerin
(OPG), in stromal and osteoblastic cells [49]. Moreover, GCs
may directly decrease apoptosis of mature osteoclasts [50].
However, discontinuation of such regimens is followed by a
high bone turnover phase [48]. In physically active patients
with MS treated with low-dose steroids, the bone turnover
markers were not diﬀerent from controls [51]. Addressing
the question of whether duration of low-dose GCs use in
combinationwithotherimmunomodulatorsinpatientswith
MSincreasesriskofosteoporosisrequiresfurtherprospective
study by taking into account other risk factors, particularly
the level of disability.
3.3. The Eﬀect of Other Immunomodulatory Drugs. Although
no harm eﬀect of low-dose methotrexate was observed
in patients with MS, several case reports have described
associations between pathological nonvertebral fractures
and low-dose methotrexate (MTX) in rheumatoid arthritis
(RA) patients [52]. In addition, methotrexate osteopathy,
characterized by pain, osteoporosis, and microfractures, has
been very rarely observed in patients with low-dose MTX
treatment [53]. Other immune-modifying drugs, such as
interferon-beta or azathioprine, which are used in conjunc-
tion with GCs have not been shown to promote bone loss
experimentally or clinically. On the contrary, interferon-
beta may have favorable eﬀect on bone metabolism in
patients with MS [54], probably due to the inhibitory
eﬀect of interferon-beta on osteoclasts development [55].
Experimentally, also treatment with the S1P(1) agonist
FTY720, a new and promising drug for the treatment of
MS, relieved ovariectomy-induced osteoporosis in mice by
reducing the number of mature osteoclasts attached to the
bonesurface[56].However,furtherinvestigationwithregard
to their eﬀects on bone health is needed.
3.4. Vitamin D Insuﬃciency. T h er o l eo fv i t a m i nDi nb o n e
homeostasis is well understood, and the use of vitamin
D to prevent and treat osteoporosis was recently reviewed
[57]. There is also evidence from both observational studies
and clinical trials that hypovitaminosis D are predisposing
conditions for various common chronic diseases. In addition
to skeletal disorders, vitamin D deﬁciency is associated with
increase the risk of malignancies, particularly of colon,
breast, and prostate gland cancer, of chronic inﬂammatory
and autoimmune diseases (e.g., insulin-dependent diabetes
mellitus, inﬂammatory bowel disease, or multiple sclerosis),4 Journal of Osteoporosis
Table 2: The mechanisms of bone loss during long-term GCs treatment.
Inhibition Stimulation
B o n ec e l l sd i r e c te ﬀects
Bone marrow/stromal cells diﬀerentiation into diﬀerentiation into
osteoblasts adipocytes
Osteoblasts diﬀerentiation, activity —
synthesis of type I collagen apoptosis
Osteocytes metabolism and function apoptosis
Osteoclasts apoptosis stimulation
Indirect eﬀects
Gut Ca2+ absorption —
Renal tubule Ca2+ reabsorption —
Parathyroid-PTH Tonic secretory rate∗ Pulse secretory
rate∗
Fractional pulsatile
secretion∗
Pituitary Growth hormone/IGF-1 —
FSH, LH —
Testes, ovaries Testosterone, estradiol —
∗Data from Bonadonna et al. [46]; abbreviations: FSH: follicle stimulating hormone; LH: luteinizing hormone; IGF-1: insulin like growth factor 1.
as well as of metabolic disorders (metabolic syndrome and
hypertension) [58]. Vitamin D intake, decreasing latitude,
increased sun exposure, and high serum vitamin D levels
have all been shown to be associated with a decreased risk
of MS [59]. Patients with MS have more often vitamin D
deﬁciency due to its low intake as well as limited sunlight
exposure [12]. Mean 25-hydroxyvitamin D3 (25OHD) levels
in patients with MS are more often lower (below the level of
20ng/mL) than in age-matched controls [11, 14]. There was
no signiﬁcant correlation between 25(OH)D and BMD in
patients with MS [11, 14]. Thus, while patients with MS are
susceptible to low 25OHD levels, the evidence implicating
linking levels to reduced BMD and osteoporosis in patients
with MS is unclear. Only a few studies have investigated this
link [11, 12, 14]. A low vitamin D state, from inadequate
diet intake and decreased exposure to sunlight, contributes
to malabsorption of calcium and vitamin D insuﬃciency in
MS patients. Secondary hyperparathyroidism may develop,
which can contribute to bone remodeling imbalance and
bone loss in patients with MS. Moreover, patients with MS
treated with GCs will be at greater risk for an imbalance
between bone formation and bone resorption and, therefore,
more susceptible to development of osteoporosis due to vita-
min D insuﬃciency/deﬁciency. GCs treatment is associated
with reduced calcium absorption from the gastrointestinal
tract by opposing vitamin D action. Furthermore, renal
tubular calcium reabsorption is also inhibited by GCs. In
addition, GCs may aﬀect PTH secretory dynamic, with a
decrease in the tonic release of PTH and an increase in
pulsatile burst of the hormone [46].
3.5. The Chronic Inﬂammatory Process of Multiple Sclerosis.
MS is an inﬂammatory disease of the central nervous system
(CNS) with a prominent role of immune cells and cytokines
in degradation of the myelin sheaths [60]. Recent evidence
has indicated that a number of additional cell types, such as
T cells, play a key role in bone loss [61]. In inﬂammatory or
autoimmune disease states, activated T-cells produce recep-
tor activator of nuclear factor kappaB ligand (RANKL) and
proinﬂammatory cytokines, such as TNF-α, IL-1, or IL-11,
allofwhichcaninduceRANKLexpressioninosteoblastsand
bone marrow stromal cells. The systemic or local activation
of T-cells may, therefore, trigger bone loss via the expression
of RANKL [61]. Osteoprotegerin (OPG), a protein member
of the tumor necrosis factor (TNF) receptor family and
its ligand RANKL were identiﬁed as a key cytokines that
regulateosteoclastogenesis[61].Signiﬁcantly,higherlevelsof
RANKL and OPG were found in the patients with MS with
low mean EDSS as compared to the age-matched controls
[62]. Among other cytokines, osteopontin (OPN) has been
studied in the shared pathogenesis of MS and osteoporosis.
OPN is a member of the SIBLING (small integrin-binding
ligand N-binding glycoprotein) family of noncollagenous
matricellular proteins [63]. OPN was identiﬁed as the most
abundantlyexpressedcytokineinMSlesions,andOPNlevels
were found to be increased in cerebrospinal ﬂuid of MS
patients[64,65]andintheplasmainpatientswithrelapsing-
remitting MS [66]. However, other studies found that OPN
circulating levels are low in patients with MS [67]. It seems
likelythatfurtherfuturestudiesexperimentswilluncoverthe
roleofOPNandadditionalmoleculesmediatingbonelossin
inﬂammatory diseases, such as MS.
3.6. Use of Antiepileptic and Antidepressant Drugs. Anti-
epileptic drug treatment can lead to osteoporosis [68, 69].
Meta-analyses have revealed that barbiturate, antidepres-
sant, antipsychotic, and benzodiazepine treatment increases
patient’s risk of osteoporosis [70]. More recently, currentJournal of Osteoporosis 5
use of antidepressant drugs with a high aﬃnity for the 5-
hydroxytryptamine reuptake transporter (5-HTT) was asso-
ciated with a higher risk of osteoporotic fractures compared
to use of antidepressants with a medium or low aﬃnity [71].
BMD was lower among those reporting current selective
serotonin reuptake inhibitors (SSRI) use but not among
users of other antidepressants [72, 73]. In vivo studies have
found that 5-HT could alter bone architecture and could
reduce bone mass and density [74]. The 5-HTT has been
locatedinosteoclasts,osteoblasts,andosteocytes,andthethe
inhibition of 5-HTT using a SSRI (ﬂuoxetine hydrochloride)
had antianabolic skeletal eﬀects in rats [74]. Further research
is needed to conﬁrm this ﬁnding in light of widespread SSRI
use and potentially important clinical implications.
4. Diagnosis and Management of Osteoporosis
inPatientswith MS
Despite the fact that patients with MS can develop osteo-
porosis and fractures more often than their age-matched
healthy controls, many patients with MS are not evaluated
for their bone status, and there are no clinical guidelines for
prevention and treatment of osteoporosis in patients with
MS. Patients with MS are also at a higher risk of falls that
can increase the frequency of bone fracture combined with
bone loss and impaired bone’s quality.
ClinicalevaluationinallpatientswithMSshouldinclude
theassessmentoftheclinicalriskfactorsforosteoporosisand
fractures, such as the hereditary disposition of osteoporosis,
previous low trauma fractures, and smoking or alcohol
habits. The speciﬁc risk factors of the osteoporosis in
patients with MS arethe level of disability (speciﬁcallymotor
disability) and possibly a long-term GCs treatment, vitamin
D deﬁciency, skeletal muscle atrophy, and increased risk of
falling. The examination of the motor function using the
EDSS score could provide a useful indicator for further
evaluation. Cutoﬀ EDSS 6 represents reasonable end of
motor performance of the patient; 6.5 means only several
meters with bilateral support, and 7 is only the ability of
transfer to wheelchair from the bed. The EDSS scores of 6
or greater has been found to correlate well with decreased
BMD [12, 15], and BMD should be routinely measured in
these patients. On the other hand, patients with a good
physical activity and low EDSS score (<5) may have normal
BMD [14]a sw e l la sm a r k e r so fb o n et u r n o v e r[ 51]. BMD
measurement should be also performed in all patients who
are receiving 5mg of prednisone equivalents daily for more
than 3 months.
BMD testing using dual-energy X-ray absorptiometry
(DXA) should be conducted at the lumbar spine and
hip. This measure provides an assessment of fracture risk
prior to the occurrence of a fragility fracture as well as
monitors the course of the disease and response to therapy.
No consensus exists as to how frequently patients at risk
osteoporosis should have followup scans. However, BMD
should be remeasured after 1 or 2 years to ascertain that it
is stable or to identify the patient with ongoing bone loss,
especially in patients treated with long-term GCs treatment.
In the presence of clinical risk factors, fracture risk may be
increasedindependentlyfromBMD.Therefore,combination
of BMD with clinical risk factors is recommended to identify
a risk patient and to target pharmacologic therapy. In
postmenopausal women and men (between 40 and 90), the
assessment of individualized 10-year absolute fracture risk
(FRAX,fracturepredictionalgorithm)isrecommended[75].
The identiﬁcation of previous low-trauma fractures,
especially vertebral fractures is important for the decision-
making process as a previous vertebral fracture is a particu-
larly strong risk factor. Importantly, vertebral fractures may
occur in 30–50% of patients receiving chronic GCs therapy
[76] and up to 50% of vertebral fractures are asymptomatic
and, therefore, do not come to the attention of physicians.
Spinal X-rays should be performed in those with localized
back pain or a loss of more than 3cm in height in order
to detect prevalent vertebral fractures. Alternatively, the
vertebral fracture assessment tool of the bone densitometer,
which is associated with low radiation, may be useful
screening test for vertebral fractures assessment.
Laboratory tests are indicated to exclude other secondary
causes of osteoporosis, such as vitamin D deﬁciency, renal
insuﬃciency, malabsorption, and hypogonadism. Useful
biochemical tests include routine standard tests to exclude
renal or hepatic impairment, blood count, serum calcium,
24-hour urinary calcium, 25-hydroxyvitamin D3 (to exclude
vitamin D deﬁciency), and gonadal hormones (to exclude
hypogonadism).
5. Treatment Options
5.1. Nonpharmacological Considerations. Prevention is more
eﬀective than treatment of established osteoporosis. For all
patients, nonpharmacological therapies should be consid-
ered for prevention of skeletal fragility, including adequate
weight-bearing exercise, nutrition (protein, calcium, vitamin
D), and lifestyle modiﬁcations. As reviewed above, disability
is the most often cause of bone loss in patients with MS, and
mechanical loading and exercise interventions can prevent
osteocyte apoptosis and bone loss [77, 78]. Exercises have
beneﬁcial eﬀects on strength, physical endurance, mobility-
related activities (transfer, balance, and walking), and on
mood, without any evidence of detrimental eﬀects [79];
however, there was no evidence that any particular exercise
programs were more eﬀective in improving or maintaining
function. Whole-body vibration is a new approach to
improve neuromuscular functions and bone strength, but
there is limited evidence that whole body vibration provides
any additional improvements [80]. Further experimental
studies are necessary to identify optimal physical activities
for the prevention of osteocyte apoptosis and bone loss.
Recurrent falls may be an important risk factor for fracture
in disabled patients with MS. In patients with MS, falls are
related to the level of disability [81], and possibly other
factors may contribute to muscle weakness and imbalance,
such as vitamin D deﬁciency or GCs treatment.
5.2. Calcium and Vitamin D. Calcium and vitamin D sup-
plementation has been routinely provided in most clinical
trials of bone protective therapy for both primary and6 Journal of Osteoporosis
secondary osteoporosis, for example, in glucocorticoid-
induced osteoporosis (GIO). The eﬀect of calcium and
vitamin D supplementation is maximized in patients whom
baseline intake is low. As patients with MS are at a higher
risk of calcium and vitamin D deﬁciency should have their
calcium and vitamin D status checked and intake must be
individualized. Those with a personal or family history of
nephrolithiasis must be screened with 24-h urinary calcium.
In immobilized patients, an increase in serum calcium is
provoked by bed rest alone and additional calcium intake
would not be helpful and might be harmful and provoke
an increased risk of kidney stone formation. However,
calcium and vitamin D should be used as an adjunct
treatment, because a low calcium intake may exacerbate
calcium loss during low mechanical loading [82]. In general,
the amount of vitamin D supplementation should aim at
achieving serum 25OHD levels above 50nmol/l in >95% of
adults without causing vitamin D toxicity. A daily dose of
800–1000IU of vitamin D3 should be able to obtain this
minimal 25OHD target. Due to vitamin D resistance in
patients receiving GCs, those patients may require amounts
of 1000–2000IU of vitamin D3 daily [83]. Measurement
of serum 25OH vitamin D is recommended, especially in
GCs-treated patients. Although some evidence suggests that
daily supplemental intake of 2000–4000IU colecalciferol is
required to obtain at least 75nmol/l 25OHD, which may
be optimum for many health outcomes [84], prospective
trialsshowing thathigher25OHDlevels(>75–80nmol/l)are
conveying additional beneﬁts without new risk are needed.
5.3. Pharmacological Interventions. The ultimate goal of all
pharmacological interventions is prevention of fractures.
Although a number of drugs have been evaluated for the
prevention and treatment of postmenopausal osteoporosis
and GIO, the evidence of their eﬃcacy in patients with MS,
especially in premenopausal women and younger men is
less strong. As osteoporosis in MS patients have multiple
pathogenesis, medical interventions used in women with
postmenopausal osteoporosis may not be similarly eﬃcient.
Patients requiring long-term GCs treatment and those being
immobilized may require pharmacological therapy to pre-
vent excessive bone loss and fractures. Options for treatment
include antiresorptive drugs, such as estrogen, or aminobis-
phosphonates, or anabolic agents such as teriparatide.
Aminobisphosphonates (BPs). Although the use of BPs
may be appropriate, the etiology of osteoporosis in patients
with MS is fundamentally diﬀerent from the osteoporosis
commonly found in the postmenopausal women for whom
these drugs were originally developed. As immobilization
in patients with MS can cause substantial bone loss and
increase in the risk of fractures [20], BPs may be option for
treatment for those patients. Although BPs have not been
systematically evaluated in the therapy of these conditions,
some studies support the potential beneﬁt of BPs in the
management of bone loss associated with immobilization
[24, 85, 86]. In immobilized patients, BPs is known to reduce
immobilization-induced hypercalcaemia by inhibiting bone
resorption of calcium. An immobilization-related elevated
serum calcium level may inhibit parathyroid hormone
(PTH) secretion, and hence renal 1, 25(OH)2D3 production,
in disabled long-standing MS patients. If oral therapy of
BPs cannot be tolerated or excluded due to gastroesophageal
disease, intravenous route of administration of ibandronate
or zolendronate may be applied. However, acute phase
reaction with fever, particularly after the ﬁrst application
of BP, may occur. BPs (alendronate, risendronate, or zolen-
dronate) were also approved for the treatment of GIO. These
drugs were shown to improve BMD, whereas the data on
fractures were scanty in GIO, particularly in premenopausal
or younger men. The mechanism by which BPs reduce the
adverse skeletal eﬀects of GCs have not been elucidated. The
disadvantage of long-term BPs treatment is that it may lead
to a reduction in bone turnover to a level inadequate to
support normal bone remodeling. Although experimental
data showed that BPsalso prevents osteocyte apoptosis, there
is also experimental evidence of increased accumulation of
microdamage with long-term BPs therapy [87]. Also, as BPs
accumulate in the skeleton (with a long-term residual time),
they cross the placenta, accumulate in fetal skeleton, and
cause toxic eﬀects in pregnant rats. Therefore, BPs should be
used with caution in women who may become pregnant.
5.4. Anabolic Drugs. Drugs, such as BPs, that suppress
bone resorption have been proposed as interventions for
prevention of GIO as well as disuse osteoporosis. The
disadvantage of this approach is that it may lead to a
reduction in bone turnover to a level inadequate to support
normal bone remodeling. An alternative approach is to
maintain a normal level of bone formation using a bone
anabolic agent such as PTH. The human recombinant N-
terminal parathyroid hormone (PTH 1–34 or teriparatide)
is a potent osteoanabolic agent, which decreases osteoblast
and osteocyte apoptosis and increases bone formation and
bone strength. Because of GCs-induced decrease in the
numberofosteoblastsandrateofboneremodeling,anabolic,
and antiapoptotic treatment with teriparatide may directly
counteracts the key pathogenetic mechanisms of GCs excess
on bone, thus, it may be a more eﬀective treatment than
BPs [88]. The same rationale applies to immobilization-
induced osteoporosis, as progressive immobilization as well
aslong-termGCsexposureresultsinosteocyteapoptosisand
reduced bone formation [89].
5.5. Future Options. As sclerostin augments osteocyte apop-
tosis, the antibody-mediated blockade of sclerostin rep-
resents a promising new therapeutic approach for the
anabolic treatment of immobilization-induced osteoporosis
and probably also for GCs-induced osteoporosis. Indeed,
morerecently,experimentaldatashowedthatadministration
of sclerostin neutralizing antibody in rat model of right
hindlimb immobilization resulted in a dramatic increase in
bone formation and a decrease in bone resorption that led to
increased trabecular and cortical bone mass [39].
6. Summary
We have described a spectrum of pathogenetic factors which
may contribute to the development of osteoporosis andJournal of Osteoporosis 7
low-trauma fractures in patients with MS. Whilst there is
evidence to support an important role for many of the
risk factors, the most signiﬁcant etiology of bone loss in
patients with MS seems to be the level of motor disability
and reduced bone load within individual patients. Other risk
factors, such as long-term GCs treatment, hypovitaminosis
D, or inﬂammation, may also play an important part in
subset of patients with MS; however, further examinations
in prospective studies are required. With regard to diagnostic
as well as therapeutic interventions, there are currently no
speciﬁc recommendations in patients with MS; however,
identiﬁcation and treatment of underlying cause should be
the goal of therapeutic management. Optimally, the patients
in a higher risk of osteoporosis should be early identiﬁed
and preventively promptly treated to avoid the bone loss
and fractures. Because the long-term disability and long-
term GCs are probably two most signiﬁcant etiologic risk
factors for osteoporosis development in the majority of the
patients withMS, the interventions whichcancounteractthe
osteocyte apoptosis as well as loss of muscle mass and muscle
weakness will be promising.
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